Speakers / World Cancer Metabolism Summit by Hanson Wade

Richard Wooster VP, Head of Cancer Metabolism GSK Richard Wooster is Vice President and Head of Cancer Metabolism Drug Discovery at GlaxoSmithKline. Prior to this he was Director of Oncology Translational Medicine at GSK. Read more...

Chi Dang Director Abramson Cancer Center The Dang laboratory provided the first mechanistic link between an oncogene and regulation of cancer cell metabolism through the identification of the lactate dehydrogenase A (LDHA) gene as a direct target of the c-Myc oncogenic transcription factor. Read more...

Paul Smith Principal Scientist - Cancer Biosciences, Oncology iMed AstraZeneca I joined AstraZeneca as a translational scientist in 2003 and have worked primarily on late discovery early development projects, currently our MEK and FGFR inhibitor programs. I lead the cancer metabolism strategy group at AstraZeneca. Read more...

Georgia Hatzivassiliou Scientist Genentech Georgia Hatzivassiliou received her B.A in Biochemistry from Oberlin College in 1992 and her Ph.D in Pathobiology from Columbia University in 2001. Read more...

Brion Murray Research Fellow Pfizer Accomplished researcher with >15 years of experience in oncology research and development. Authored 32 manuscripts with 15 patents. Co-discovered the IB kinases and JNK inhibitor SP600125 while at Signal Pharmaceuticals (now Celgene). Read more...

Kenneth Bair SVP, Head of R&D Forma Therapeutics Kenneth W. Bair, PhD has worked on cancer drug discovery for over 30 years. He has held scientific/management positions at Burroughs Wellcome, Sandoz, Novartis, Pharmacia, Chiron & Entremed before coming to Forma Therapeutics as SVP & Head of R&D. Read more...

Rolf Witte CEO Warburg Glycomed Rolf is a trained lawyer and accountant who worked in the life science industry for the last 12 years, mainly in medical devices and drug development. Exploring really new modes of action to find new ways to cover medical needs for broad patient populations has ignited his interest in energy metabolism. Read more...

Mark Matteucci Sr. Vice President, Discovery Threshold Pharmaceuticals I joined Threshold Pharmaceuticals at its inception and was the initiator and champion for our hypoxia activated prodrug program. I was an early scientist at Genentech and a founding scientist at Gilead Sciences. I was educated at MIT and University of Colorado. Read more...

Robert Carlson VP, Head of Research Myrexis Robert Carlson is the Head of Research at Myrexis, Inc. and has led the Company's drug discovery efforts since 2004. Dr. Carlson has over 18 years of experience in small molecule drug discovery and preclinical development with both large and small pharmaceutical companies Read more...

Charles Kung Senior Scientist, Biology Agios Pharmaceuticals Charles Kung received his Ph.D. in Chemistry & Chemical Biology from UCSF studying pharmacological modulation of protein kinase signaling in the laboratory of Dr. Kevan Shokat. Read more...

Johannes Coy CEO Tavargenix Biologist Johannes Coy worked at the German Cancer Research Center from 1990 to 2001. In 2001 he moved to mtm laboratories. 2004 he joined R-Biopharm as head of oncology. Read more...

Michael P. Lisanti Director, Stem Cell Biology and Regenerative Medicine Center Kimmel Cancer Center Professor of Cancer Biology, Medical Oncology, and Biochemistry Kimmel Cancer Center, Thomas Jefferson University, Bluemle Life Sciences Building, 9th Floor. Read more...

Robert Rodriguez President, Chief Operating Officer and Co-founder Cornerstone Pharmaceuticals, Inc. Mr. Rodriguez has nearly 30 years of life and health sciences related experience having held scientific, management and consulting positions at large corporations and entrepreneurial ventures. Read more...

Gilles Tapolsky CEO Advanced Cancer Therapeutics (ACT) Dr. Tapolsky is responsible for the preclinical and clinical activities. Prior to joining ACT, He was at Tapestry Pharmaceuticals developing new anti-cancer agents and at FeRx Inc. where he led the drug discovery efforts. Read more...

Ray Tabibiazar President and CEO Ruga Corporation Dr. Tabibiazar, MD, is a clinician scientist and former Venture Partner at Bay City Capital. He was the founder and CSO of Aviir, a venture-backed diagnostic company in the Bay Area focusing on metabolic and molecular underpinnings of cardiovascular disease. Read more...

Christopher Moy Investigator - Biology GlaxoSmithKline, Oncology R&D, Translational Medicine, Cancer Metabolism Drug Discovery Chris Moy works at GlaxoSmithKline Oncology R&D in Cancer Metabolism/Translational Medicine and has a background in computational biology. Read more...

Lars Ährlund-Richter CSO Kancera AB Lars Ährlund-Richter, Ph.D. is Since 2010 CSO at Kancera AB, Stockholm, Sweden and Professor of Molecular Embryology at the Dept. of Women’s and Children’s Health, Karolinska Institute, Stockholm, Sweden, and M.Sc. in chemistry and biology at Stockholm University. Read more...

Gary D. Glick Werner E. Bachmann Professor, Chemistry University of Michigan Prof. Glick trained at Columbia University and Harvard University, and since 1990 has been on the chemistry faculty at the University of Michigan. Read more...

Sergey Kozmin Professor, Department of Chemistry University of Chicago Sergey Kozmin was born in Moscow, Russia and received his Undergraduate Diploma at the Moscow State University in 1993. He obtained his Ph.D. in 1998 at the University of Chicago and completed postdoctoral studies in 2000 at the University of Pennsylvania. Read more...